SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SON-DP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Go deeper with GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SON-DP overview
The drug candidates are under development for the treatment of metastatic solid tumors like pancreatic, ovarian, colorectal, and triple-negative breast cancers. The drug candidates are administered through intravenous route. These are developed based on protein-induced in-situ cell reprogramming technology.
The drug candidates were under development for the treatment of glioma.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataQurgen overview
Qurgen., a provider of protein induced pluripotent stem cells. The company is headquartered in United States.
For a complete picture of SON-DP’s drug-specific PTSR and LoA scores, buy the report here.
